Publications
- Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis2014 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines2014 | First Faculty of Medicine, Second Faculty of Medicine
- Denosumab - a new potential effect of RANKL inhibitor2014 | Second Faculty of Medicine
- Second line therapy for metastatic renal cell carcinoma2013 | First Faculty of Medicine, Second Faculty of Medicine
- Pazopanib vs. sunitinib in terms of patient preference - results of the PISCES study2012 | Second Faculty of Medicine
- VEGFREverolimus in the treatment of metastatic renal cell carcinoma - subanalysis of patients from the RECORD-1 study pretreated with one vs. two VEGFR inhibitors2012 | Second Faculty of Medicine
- Pazopanib in the treatment of renal cell carcinoma2012 | Second Faculty of Medicine
- Lapatinib in combination with aromatase inhibitors in the treatment of breast cancer2011 | Publication without faculty affiliation
- Kidney cancer. What is the next step after failure of treatment with angiogenesis inhibitors?2010 | Second Faculty of Medicine
- Integrative analysis of mRNA and miRNA expression profiles and somatic variants in oxysterol signaling in early-stage luminal breast cancer2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
Loading network view...
